You don't understand how clinical trials work and how they are designed. Azer Cell is given fourth in line - this will mean if it gets through registerational trial to commercially be given to patients it will not be given first as SOC (or even in combo with first), it won't be given second or third but fourth. Its really importbat to grasp this amd this is how IMU have setup up with the trial.
Imu even have in their presentations where they talk about the market size of their patient pool which they are targeting. That is patients/people who have relapsed from carT autolopgus - a segment of the population of DLCBC sufferers.
Imu themselves know this - you need to get this.
IMU Price at posting:
4.1¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)